Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)

BACKGROUND Age-related macular degeneration is a potential indication for anti-amyloid therapy: • Amyloid beta (Aβ) has been identified in drusen 1,2 • Aβ increases levels of VEGF secretion by the retinal pigment epithelium (RPE)3,4 • A β 1-40 decrease levels of pigment epitheliumderived factor (PEDF) secretion by RPE5 • Efficacy was shown in dry AMD using a mouse model. Weekly intraperitoneal injections of antiAβ 40/42 resulted in normalization of the scotopic ERG b-wave5. RESULTS CONTINUED